| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 260 | 2026 | 727 | 39.920 |
Why?
|
| Stroke Volume | 165 | 2026 | 417 | 25.240 |
Why?
|
| Exercise Tolerance | 65 | 2025 | 119 | 13.540 |
Why?
|
| Exercise Therapy | 53 | 2026 | 249 | 7.680 |
Why?
|
| Ventricular Function, Left | 70 | 2025 | 264 | 7.360 |
Why?
|
| Oxygen Consumption | 59 | 2025 | 140 | 6.990 |
Why?
|
| Obesity | 54 | 2025 | 1108 | 6.420 |
Why?
|
| Exercise | 51 | 2025 | 605 | 6.190 |
Why?
|
| Humans | 402 | 2026 | 32284 | 5.060 |
Why?
|
| Aged | 245 | 2026 | 10257 | 5.010 |
Why?
|
| Aging | 34 | 2026 | 941 | 4.590 |
Why?
|
| Ventricular Dysfunction, Left | 40 | 2023 | 168 | 4.290 |
Why?
|
| Female | 288 | 2026 | 19954 | 4.090 |
Why?
|
| Male | 284 | 2026 | 19434 | 4.050 |
Why?
|
| Exercise Test | 49 | 2024 | 218 | 3.630 |
Why?
|
| Quality of Life | 42 | 2026 | 971 | 3.340 |
Why?
|
| Hypertension | 51 | 2025 | 983 | 3.310 |
Why?
|
| Glucagon-Like Peptides | 15 | 2025 | 16 | 3.160 |
Why?
|
| Middle Aged | 193 | 2026 | 11843 | 3.100 |
Why?
|
| Heart Rate | 25 | 2025 | 364 | 2.770 |
Why?
|
| Cardiovascular Diseases | 31 | 2024 | 1159 | 2.710 |
Why?
|
| Aged, 80 and over | 88 | 2026 | 3896 | 2.640 |
Why?
|
| Diastole | 33 | 2023 | 98 | 2.460 |
Why?
|
| Atherosclerosis | 18 | 2024 | 806 | 2.250 |
Why?
|
| Echocardiography | 42 | 2025 | 190 | 2.200 |
Why?
|
| Caloric Restriction | 8 | 2024 | 91 | 2.160 |
Why?
|
| Randomized Controlled Trials as Topic | 23 | 2026 | 548 | 2.100 |
Why?
|
| Muscle, Skeletal | 13 | 2023 | 520 | 2.100 |
Why?
|
| Blood Pressure | 34 | 2025 | 866 | 2.020 |
Why?
|
| Double-Blind Method | 33 | 2025 | 566 | 2.000 |
Why?
|
| Hospitalization | 30 | 2024 | 476 | 1.980 |
Why?
|
| Treatment Outcome | 61 | 2025 | 3410 | 1.820 |
Why?
|
| Nitrates | 3 | 2024 | 29 | 1.770 |
Why?
|
| Heart Ventricles | 14 | 2020 | 146 | 1.690 |
Why?
|
| Antihypertensive Agents | 17 | 2025 | 364 | 1.680 |
Why?
|
| Heart Failure, Diastolic | 6 | 2017 | 15 | 1.570 |
Why?
|
| Spironolactone | 5 | 2019 | 11 | 1.560 |
Why?
|
| Glucosides | 10 | 2024 | 13 | 1.510 |
Why?
|
| Benzhydryl Compounds | 10 | 2024 | 23 | 1.490 |
Why?
|
| Heart | 9 | 2018 | 177 | 1.460 |
Why?
|
| Caregivers | 5 | 2019 | 114 | 1.420 |
Why?
|
| Risk Factors | 63 | 2024 | 3938 | 1.400 |
Why?
|
| Echocardiography, Doppler | 22 | 2021 | 44 | 1.360 |
Why?
|
| Body Composition | 9 | 2025 | 327 | 1.310 |
Why?
|
| Physical Endurance | 8 | 2017 | 40 | 1.310 |
Why?
|
| Follow-Up Studies | 45 | 2025 | 2238 | 1.310 |
Why?
|
| Resistance Training | 3 | 2025 | 59 | 1.280 |
Why?
|
| Diabetes Mellitus, Type 2 | 19 | 2025 | 1436 | 1.260 |
Why?
|
| Systole | 16 | 2019 | 94 | 1.230 |
Why?
|
| Age Factors | 30 | 2025 | 1179 | 1.210 |
Why?
|
| Prognosis | 49 | 2020 | 1529 | 1.170 |
Why?
|
| Coronary Vessels | 3 | 2017 | 173 | 1.140 |
Why?
|
| United States | 55 | 2026 | 4079 | 1.140 |
Why?
|
| Weight Loss | 15 | 2025 | 410 | 1.130 |
Why?
|
| Empathy | 2 | 2019 | 17 | 1.090 |
Why?
|
| Frail Elderly | 6 | 2026 | 69 | 1.090 |
Why?
|
| Physicians | 2 | 2020 | 163 | 1.070 |
Why?
|
| Time Factors | 35 | 2025 | 2196 | 1.060 |
Why?
|
| Heart Failure, Systolic | 10 | 2014 | 15 | 1.040 |
Why?
|
| Risk Assessment | 22 | 2019 | 1424 | 1.030 |
Why?
|
| Hemodynamics | 9 | 2019 | 164 | 1.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 8 | 2018 | 133 | 1.030 |
Why?
|
| Prospective Studies | 40 | 2025 | 2320 | 1.020 |
Why?
|
| Drug Therapy, Combination | 5 | 2024 | 293 | 1.020 |
Why?
|
| Hypertrophy, Left Ventricular | 18 | 2017 | 122 | 0.990 |
Why?
|
| Natriuretic Peptide, Brain | 18 | 2024 | 86 | 0.980 |
Why?
|
| Activities of Daily Living | 4 | 2016 | 246 | 0.970 |
Why?
|
| Comorbidity | 19 | 2019 | 563 | 0.970 |
Why?
|
| Endothelium, Vascular | 5 | 2016 | 153 | 0.940 |
Why?
|
| Heart Diseases | 7 | 2019 | 114 | 0.890 |
Why?
|
| Clinical Trials as Topic | 8 | 2026 | 312 | 0.870 |
Why?
|
| Peptide Fragments | 15 | 2024 | 417 | 0.860 |
Why?
|
| Allopurinol | 1 | 2024 | 13 | 0.850 |
Why?
|
| Single-Blind Method | 11 | 2026 | 192 | 0.830 |
Why?
|
| Chronic Disease | 19 | 2025 | 411 | 0.830 |
Why?
|
| Life Style | 8 | 2025 | 394 | 0.800 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2021 | 1211 | 0.790 |
Why?
|
| Myocardium | 7 | 2018 | 184 | 0.790 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2023 | 27 | 0.780 |
Why?
|
| Dementia | 5 | 2025 | 246 | 0.770 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2023 | 13 | 0.760 |
Why?
|
| Disease Management | 4 | 2017 | 129 | 0.760 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 7 | 2025 | 116 | 0.760 |
Why?
|
| Cognition Disorders | 2 | 2015 | 349 | 0.740 |
Why?
|
| Ventricular Remodeling | 9 | 2024 | 63 | 0.740 |
Why?
|
| Rest | 2 | 2019 | 49 | 0.730 |
Why?
|
| Atrial Function, Left | 6 | 2016 | 22 | 0.720 |
Why?
|
| Geriatrics | 5 | 2023 | 86 | 0.720 |
Why?
|
| Adult | 49 | 2025 | 9263 | 0.700 |
Why?
|
| Case-Control Studies | 13 | 2021 | 858 | 0.670 |
Why?
|
| Body Mass Index | 19 | 2020 | 863 | 0.660 |
Why?
|
| Prevalence | 23 | 2021 | 960 | 0.650 |
Why?
|
| Severity of Illness Index | 16 | 2025 | 851 | 0.640 |
Why?
|
| Outpatients | 6 | 2020 | 57 | 0.640 |
Why?
|
| Intergenerational Relations | 1 | 2020 | 1 | 0.640 |
Why?
|
| Child Rearing | 1 | 2020 | 4 | 0.640 |
Why?
|
| Love | 2 | 2020 | 4 | 0.630 |
Why?
|
| Incidence | 24 | 2025 | 1244 | 0.630 |
Why?
|
| Phenotype | 11 | 2025 | 619 | 0.620 |
Why?
|
| Cardiology | 5 | 2019 | 104 | 0.620 |
Why?
|
| African Americans | 14 | 2020 | 1335 | 0.620 |
Why?
|
| Atrial Fibrillation | 5 | 2024 | 410 | 0.620 |
Why?
|
| Anaerobic Threshold | 4 | 2010 | 5 | 0.600 |
Why?
|
| Beta vulgaris | 2 | 2017 | 11 | 0.600 |
Why?
|
| Proportional Hazards Models | 19 | 2018 | 773 | 0.590 |
Why?
|
| Research Design | 10 | 2025 | 316 | 0.590 |
Why?
|
| Predictive Value of Tests | 24 | 2023 | 880 | 0.580 |
Why?
|
| Walking | 7 | 2023 | 199 | 0.580 |
Why?
|
| Muscle Strength | 4 | 2025 | 136 | 0.570 |
Why?
|
| Diuretics | 7 | 2024 | 28 | 0.570 |
Why?
|
| Body Fat Distribution | 2 | 2018 | 25 | 0.570 |
Why?
|
| Tetrazoles | 4 | 2018 | 61 | 0.560 |
Why?
|
| Cohort Studies | 26 | 2020 | 1840 | 0.560 |
Why?
|
| Motor Activity | 3 | 2016 | 332 | 0.560 |
Why?
|
| Social Support | 1 | 2019 | 181 | 0.550 |
Why?
|
| Fumarates | 1 | 2018 | 1 | 0.550 |
Why?
|
| Abdominal Fat | 1 | 2018 | 39 | 0.550 |
Why?
|
| Amides | 1 | 2018 | 24 | 0.540 |
Why?
|
| Adrenergic beta-Antagonists | 6 | 2020 | 58 | 0.540 |
Why?
|
| Neprilysin | 1 | 2018 | 31 | 0.540 |
Why?
|
| Biomedical Research | 3 | 2026 | 178 | 0.540 |
Why?
|
| Quadriceps Muscle | 2 | 2016 | 29 | 0.540 |
Why?
|
| Sex Factors | 15 | 2025 | 656 | 0.540 |
Why?
|
| Cognition | 6 | 2025 | 548 | 0.540 |
Why?
|
| Carotid Arteries | 3 | 2013 | 110 | 0.530 |
Why?
|
| Patient Selection | 5 | 2019 | 272 | 0.520 |
Why?
|
| Fathers | 1 | 2017 | 12 | 0.510 |
Why?
|
| Diabetic Angiopathies | 3 | 2018 | 149 | 0.500 |
Why?
|
| Parent-Child Relations | 1 | 2017 | 45 | 0.500 |
Why?
|
| Mitral Valve Stenosis | 1 | 2016 | 9 | 0.490 |
Why?
|
| Pyridines | 3 | 2024 | 79 | 0.490 |
Why?
|
| Acute Disease | 8 | 2026 | 253 | 0.490 |
Why?
|
| Dyspnea | 5 | 2023 | 32 | 0.490 |
Why?
|
| Inflammation | 9 | 2024 | 500 | 0.490 |
Why?
|
| Physical Fitness | 5 | 2017 | 120 | 0.490 |
Why?
|
| Cardiac Output | 6 | 2019 | 33 | 0.480 |
Why?
|
| GTP Phosphohydrolases | 1 | 2016 | 7 | 0.480 |
Why?
|
| Mitochondria, Muscle | 1 | 2016 | 18 | 0.480 |
Why?
|
| Cardiomyopathies | 4 | 2024 | 67 | 0.480 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2019 | 293 | 0.470 |
Why?
|
| Carotid Artery Diseases | 2 | 2017 | 127 | 0.470 |
Why?
|
| Lung | 3 | 2025 | 264 | 0.470 |
Why?
|
| Diabetic Nephropathies | 4 | 2019 | 222 | 0.470 |
Why?
|
| Dietary Supplements | 1 | 2017 | 187 | 0.460 |
Why?
|
| Arrhythmias, Cardiac | 4 | 2017 | 100 | 0.460 |
Why?
|
| Myocardial Infarction | 10 | 2018 | 466 | 0.460 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 72 | 0.450 |
Why?
|
| Leg | 3 | 2016 | 67 | 0.450 |
Why?
|
| Benzazepines | 1 | 2015 | 25 | 0.450 |
Why?
|
| Myocardial Contraction | 7 | 2009 | 59 | 0.450 |
Why?
|
| American Heart Association | 6 | 2019 | 92 | 0.450 |
Why?
|
| European Continental Ancestry Group | 13 | 2020 | 1076 | 0.450 |
Why?
|
| Spinal Neoplasms | 1 | 2015 | 21 | 0.440 |
Why?
|
| Reproducibility of Results | 12 | 2025 | 755 | 0.440 |
Why?
|
| Endomyocardial Fibrosis | 1 | 2014 | 3 | 0.440 |
Why?
|
| Cardiotonic Agents | 3 | 2017 | 41 | 0.440 |
Why?
|
| Cardiac Output, Low | 3 | 2015 | 9 | 0.430 |
Why?
|
| Cardiomegaly | 1 | 2014 | 29 | 0.430 |
Why?
|
| Sarcopenia | 1 | 2015 | 50 | 0.430 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2013 | 5 | 0.430 |
Why?
|
| Enalapril | 2 | 2015 | 8 | 0.430 |
Why?
|
| Home Care Services | 3 | 2019 | 51 | 0.420 |
Why?
|
| Reference Values | 6 | 2014 | 238 | 0.420 |
Why?
|
| Amyloidosis | 2 | 2015 | 16 | 0.420 |
Why?
|
| Cross-Sectional Studies | 17 | 2025 | 1485 | 0.420 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 394 | 0.410 |
Why?
|
| Continental Population Groups | 6 | 2020 | 228 | 0.410 |
Why?
|
| Dobutamine | 4 | 2018 | 54 | 0.400 |
Why?
|
| Glomerular Filtration Rate | 5 | 2024 | 302 | 0.400 |
Why?
|
| Glucagon-Like Peptide 1 | 4 | 2025 | 13 | 0.400 |
Why?
|
| Cardiovascular System | 3 | 2025 | 49 | 0.400 |
Why?
|
| Biphenyl Compounds | 2 | 2012 | 21 | 0.390 |
Why?
|
| Diabetes Mellitus | 5 | 2023 | 390 | 0.390 |
Why?
|
| Multivariate Analysis | 14 | 2017 | 650 | 0.390 |
Why?
|
| Hypoglycemic Agents | 3 | 2025 | 186 | 0.390 |
Why?
|
| Physical Exertion | 3 | 2012 | 15 | 0.390 |
Why?
|
| Calcium | 2 | 2018 | 337 | 0.380 |
Why?
|
| Magnetic Resonance Imaging, Cine | 4 | 2025 | 99 | 0.380 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2012 | 66 | 0.380 |
Why?
|
| Health Status Disparities | 2 | 2012 | 128 | 0.380 |
Why?
|
| Anthracyclines | 3 | 2019 | 52 | 0.380 |
Why?
|
| Adiposity | 3 | 2019 | 190 | 0.370 |
Why?
|
| Coronary Artery Disease | 7 | 2017 | 427 | 0.370 |
Why?
|
| Patient Compliance | 5 | 2024 | 206 | 0.360 |
Why?
|
| Multicenter Studies as Topic | 6 | 2026 | 110 | 0.350 |
Why?
|
| Patient Education as Topic | 5 | 2020 | 245 | 0.350 |
Why?
|
| Oxygen | 4 | 2017 | 134 | 0.340 |
Why?
|
| Blood Flow Velocity | 4 | 2009 | 77 | 0.340 |
Why?
|
| Decision Making | 3 | 2026 | 190 | 0.340 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2024 | 14 | 0.340 |
Why?
|
| Chi-Square Distribution | 9 | 2017 | 287 | 0.330 |
Why?
|
| Young Adult | 9 | 2019 | 2652 | 0.330 |
Why?
|
| Geriatric Assessment | 6 | 2019 | 335 | 0.330 |
Why?
|
| Societies, Medical | 3 | 2019 | 153 | 0.330 |
Why?
|
| Animals | 19 | 2025 | 8165 | 0.330 |
Why?
|
| Fatty Acids, Volatile | 3 | 2019 | 10 | 0.330 |
Why?
|
| Registries | 2 | 2021 | 294 | 0.330 |
Why?
|
| Diabetes Complications | 3 | 2020 | 171 | 0.320 |
Why?
|
| Physical Education and Training | 1 | 2010 | 12 | 0.320 |
Why?
|
| Cardiovascular Agents | 3 | 2018 | 17 | 0.320 |
Why?
|
| Posture | 1 | 2010 | 62 | 0.310 |
Why?
|
| Research | 3 | 2020 | 81 | 0.310 |
Why?
|
| Acne Vulgaris | 1 | 2021 | 101 | 0.310 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2018 | 19 | 0.300 |
Why?
|
| Skin Diseases | 1 | 2021 | 135 | 0.300 |
Why?
|
| Naphthalenes | 2 | 2024 | 53 | 0.290 |
Why?
|
| Troponin T | 4 | 2024 | 92 | 0.290 |
Why?
|
| Dipeptides | 2 | 2019 | 7 | 0.290 |
Why?
|
| Lung Diseases | 2 | 2019 | 50 | 0.290 |
Why?
|
| Health Status | 3 | 2024 | 356 | 0.290 |
Why?
|
| Disability Evaluation | 3 | 2017 | 241 | 0.280 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2020 | 96 | 0.280 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2019 | 69 | 0.280 |
Why?
|
| Blood Glucose | 2 | 2015 | 484 | 0.280 |
Why?
|
| Ultrasonography | 6 | 2015 | 394 | 0.270 |
Why?
|
| Longitudinal Studies | 8 | 2017 | 760 | 0.270 |
Why?
|
| Recovery of Function | 4 | 2025 | 236 | 0.270 |
Why?
|
| Depression | 5 | 2019 | 427 | 0.270 |
Why?
|
| Dermatologic Agents | 1 | 2021 | 233 | 0.260 |
Why?
|
| Accidental Falls | 2 | 2019 | 104 | 0.260 |
Why?
|
| Body Weight | 5 | 2023 | 323 | 0.260 |
Why?
|
| Hispanic Americans | 3 | 2018 | 772 | 0.260 |
Why?
|
| Electrocardiography | 7 | 2018 | 624 | 0.260 |
Why?
|
| Preoperative Care | 3 | 2020 | 126 | 0.260 |
Why?
|
| Echocardiography, Three-Dimensional | 4 | 2018 | 8 | 0.260 |
Why?
|
| Gait | 3 | 2020 | 121 | 0.260 |
Why?
|
| Carbon Dioxide | 6 | 2010 | 35 | 0.260 |
Why?
|
| Metabolomics | 2 | 2024 | 63 | 0.250 |
Why?
|
| Prealbumin | 3 | 2015 | 7 | 0.250 |
Why?
|
| Respiration | 2 | 2023 | 30 | 0.250 |
Why?
|
| Linear Models | 9 | 2016 | 426 | 0.250 |
Why?
|
| Aorta | 3 | 2005 | 120 | 0.250 |
Why?
|
| Aortic Valve | 3 | 2007 | 58 | 0.240 |
Why?
|
| Homeostasis | 3 | 2018 | 130 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2020 | 821 | 0.240 |
Why?
|
| African Continental Ancestry Group | 6 | 2020 | 338 | 0.240 |
Why?
|
| Arteries | 1 | 2006 | 75 | 0.240 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2026 | 7 | 0.240 |
Why?
|
| Cause of Death | 10 | 2019 | 236 | 0.240 |
Why?
|
| Aortic Valve Stenosis | 2 | 2005 | 40 | 0.240 |
Why?
|
| Psoriasis | 1 | 2021 | 355 | 0.240 |
Why?
|
| Terminology as Topic | 1 | 2006 | 68 | 0.230 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 61 | 0.230 |
Why?
|
| Genome, Human | 3 | 2020 | 130 | 0.230 |
Why?
|
| Sertraline | 2 | 2017 | 27 | 0.230 |
Why?
|
| Postural Balance | 2 | 2017 | 142 | 0.230 |
Why?
|
| Serotonin Uptake Inhibitors | 2 | 2017 | 41 | 0.230 |
Why?
|
| Aldosterone | 3 | 2018 | 26 | 0.230 |
Why?
|
| Drug Combinations | 3 | 2021 | 102 | 0.230 |
Why?
|
| Models, Cardiovascular | 2 | 2020 | 31 | 0.230 |
Why?
|
| Pyrrolidines | 2 | 2015 | 15 | 0.230 |
Why?
|
| Forecasting | 4 | 2017 | 144 | 0.230 |
Why?
|
| Heart Atria | 6 | 2023 | 81 | 0.230 |
Why?
|
| Echocardiography, Stress | 2 | 2015 | 23 | 0.220 |
Why?
|
| Feces | 3 | 2019 | 50 | 0.220 |
Why?
|
| Hyperkalemia | 2 | 2018 | 15 | 0.220 |
Why?
|
| Potassium | 2 | 2018 | 40 | 0.220 |
Why?
|
| Propionates | 1 | 2024 | 8 | 0.210 |
Why?
|
| Defibrillators, Implantable | 2 | 2023 | 44 | 0.210 |
Why?
|
| Polymers | 2 | 2018 | 65 | 0.210 |
Why?
|
| Uric Acid | 1 | 2024 | 26 | 0.210 |
Why?
|
| Mortality | 3 | 2016 | 122 | 0.210 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2016 | 72 | 0.210 |
Why?
|
| Coronary Disease | 3 | 2016 | 226 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2019 | 709 | 0.210 |
Why?
|
| Cerebrovascular Circulation | 1 | 2025 | 93 | 0.210 |
Why?
|
| Baroreflex | 1 | 2025 | 86 | 0.210 |
Why?
|
| Flavins | 1 | 2023 | 6 | 0.200 |
Why?
|
| Luciferases | 1 | 2023 | 33 | 0.200 |
Why?
|
| Food | 1 | 2024 | 42 | 0.200 |
Why?
|
| Population Surveillance | 2 | 2018 | 120 | 0.200 |
Why?
|
| Pulmonary Artery | 1 | 2023 | 25 | 0.200 |
Why?
|
| Orthopedic Nursing | 2 | 2020 | 4 | 0.200 |
Why?
|
| Memory | 2 | 2018 | 202 | 0.200 |
Why?
|
| Proteomics | 1 | 2024 | 96 | 0.200 |
Why?
|
| Lactic Acid | 2 | 2019 | 56 | 0.190 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 388 | 0.190 |
Why?
|
| Diseases in Twins | 1 | 2003 | 9 | 0.190 |
Why?
|
| Creatinine | 3 | 2019 | 191 | 0.190 |
Why?
|
| Pulmonary Ventilation | 4 | 2010 | 12 | 0.190 |
Why?
|
| Stress, Physiological | 2 | 2014 | 53 | 0.190 |
Why?
|
| Inulin | 2 | 2019 | 2 | 0.190 |
Why?
|
| Patient Discharge | 3 | 2017 | 204 | 0.190 |
Why?
|
| Survival Rate | 10 | 2017 | 892 | 0.190 |
Why?
|
| Age Distribution | 3 | 2016 | 194 | 0.190 |
Why?
|
| Family Health | 2 | 2018 | 73 | 0.190 |
Why?
|
| Authorship | 2 | 2015 | 9 | 0.190 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2023 | 61 | 0.180 |
Why?
|
| Prebiotics | 2 | 2019 | 4 | 0.180 |
Why?
|
| Respiratory Tract Diseases | 2 | 2012 | 34 | 0.180 |
Why?
|
| Disease Progression | 7 | 2018 | 590 | 0.180 |
Why?
|
| Aortic Diseases | 1 | 2002 | 59 | 0.180 |
Why?
|
| Probiotics | 2 | 2019 | 9 | 0.180 |
Why?
|
| Sensitivity and Specificity | 6 | 2014 | 555 | 0.180 |
Why?
|
| Analysis of Variance | 6 | 2015 | 470 | 0.180 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2021 | 1 | 0.180 |
Why?
|
| Cross-Over Studies | 4 | 2016 | 96 | 0.170 |
Why?
|
| Capillaries | 2 | 2014 | 25 | 0.170 |
Why?
|
| Glucose | 4 | 2023 | 158 | 0.170 |
Why?
|
| Odds Ratio | 4 | 2019 | 455 | 0.170 |
Why?
|
| Kidney Failure, Chronic | 3 | 2018 | 532 | 0.170 |
Why?
|
| C-Reactive Protein | 5 | 2024 | 226 | 0.160 |
Why?
|
| MicroRNAs | 1 | 2023 | 181 | 0.160 |
Why?
|
| Hormone Replacement Therapy | 2 | 2015 | 94 | 0.160 |
Why?
|
| Organotechnetium Compounds | 2 | 2011 | 2 | 0.160 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2011 | 20 | 0.160 |
Why?
|
| Body Size | 3 | 2012 | 35 | 0.160 |
Why?
|
| Organophosphorus Compounds | 2 | 2011 | 30 | 0.160 |
Why?
|
| Metformin | 1 | 2020 | 25 | 0.160 |
Why?
|
| Brain | 2 | 2025 | 966 | 0.160 |
Why?
|
| Emotions | 1 | 2020 | 55 | 0.160 |
Why?
|
| Physical Therapy Modalities | 2 | 2017 | 81 | 0.160 |
Why?
|
| Nurses | 1 | 2020 | 14 | 0.150 |
Why?
|
| Absorptiometry, Photon | 2 | 2018 | 98 | 0.150 |
Why?
|
| Thigh | 2 | 2018 | 35 | 0.150 |
Why?
|
| Perception | 1 | 2020 | 99 | 0.150 |
Why?
|
| Ovariectomy | 2 | 2018 | 202 | 0.150 |
Why?
|
| Hand Strength | 5 | 2025 | 98 | 0.150 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 35 | 0.150 |
Why?
|
| Myocytes, Cardiac | 2 | 2017 | 89 | 0.150 |
Why?
|
| Algorithms | 3 | 2020 | 537 | 0.150 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2019 | 7 | 0.150 |
Why?
|
| Vasodilation | 3 | 2010 | 93 | 0.150 |
Why?
|
| Kidney | 3 | 2018 | 520 | 0.150 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2019 | 8 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 98 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 95 | 0.150 |
Why?
|
| Blood Pressure Determination | 4 | 2025 | 106 | 0.150 |
Why?
|
| Polysaccharides | 1 | 2019 | 11 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2019 | 554 | 0.140 |
Why?
|
| Life Change Events | 1 | 2018 | 20 | 0.140 |
Why?
|
| Alcohol Drinking | 2 | 2015 | 256 | 0.140 |
Why?
|
| Cardiotoxins | 1 | 2018 | 9 | 0.140 |
Why?
|
| Problem Solving | 1 | 2018 | 26 | 0.140 |
Why?
|
| Cardiovascular Physiological Phenomena | 2 | 2017 | 18 | 0.140 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2018 | 12 | 0.140 |
Why?
|
| Plasma Volume | 1 | 2018 | 1 | 0.140 |
Why?
|
| Mobility Limitation | 2 | 2017 | 208 | 0.140 |
Why?
|
| Oxidative Stress | 2 | 2017 | 241 | 0.140 |
Why?
|
| Intra-Abdominal Fat | 1 | 2018 | 58 | 0.140 |
Why?
|
| Heart-Assist Devices | 2 | 2016 | 31 | 0.130 |
Why?
|
| Estradiol | 1 | 2018 | 139 | 0.130 |
Why?
|
| Syncope | 1 | 2018 | 25 | 0.130 |
Why?
|
| Continuity of Patient Care | 2 | 2017 | 73 | 0.130 |
Why?
|
| Myocardial Ischemia | 1 | 2018 | 98 | 0.130 |
Why?
|
| Kidney Diseases | 2 | 2017 | 242 | 0.130 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2017 | 11 | 0.130 |
Why?
|
| Hypotension | 1 | 2018 | 43 | 0.130 |
Why?
|
| Acute Coronary Syndrome | 2 | 2017 | 167 | 0.130 |
Why?
|
| Morbidity | 2 | 2016 | 98 | 0.130 |
Why?
|
| Vitamin D Deficiency | 1 | 2018 | 87 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 550 | 0.130 |
Why?
|
| Sex Characteristics | 2 | 2016 | 173 | 0.130 |
Why?
|
| Self Care | 3 | 2013 | 97 | 0.130 |
Why?
|
| Carotid Artery, Common | 1 | 2017 | 48 | 0.130 |
Why?
|
| Gene Expression | 1 | 2018 | 345 | 0.130 |
Why?
|
| Growth Hormone | 2 | 2008 | 15 | 0.130 |
Why?
|
| Premenopause | 1 | 2017 | 53 | 0.130 |
Why?
|
| Nitrites | 1 | 2017 | 22 | 0.130 |
Why?
|
| Muscular Diseases | 1 | 2017 | 23 | 0.130 |
Why?
|
| Regression Analysis | 5 | 2012 | 273 | 0.130 |
Why?
|
| Career Mobility | 1 | 2017 | 17 | 0.130 |
Why?
|
| Overweight | 3 | 2018 | 252 | 0.130 |
Why?
|
| Vitamin D | 1 | 2018 | 186 | 0.120 |
Why?
|
| Random Allocation | 4 | 2019 | 246 | 0.120 |
Why?
|
| Extracellular Matrix | 1 | 2018 | 255 | 0.120 |
Why?
|
| Receptors, Cell Surface | 2 | 2014 | 78 | 0.120 |
Why?
|
| Angiotensin II | 2 | 2009 | 241 | 0.120 |
Why?
|
| Publishing | 2 | 2015 | 66 | 0.120 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2014 | 24 | 0.120 |
Why?
|
| Pacemaker, Artificial | 2 | 2014 | 40 | 0.120 |
Why?
|
| Citrate (si)-Synthase | 1 | 2016 | 1 | 0.120 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 1 | 2016 | 2 | 0.120 |
Why?
|
| Mice | 5 | 2023 | 2544 | 0.120 |
Why?
|
| Residence Characteristics | 2 | 2016 | 179 | 0.120 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2016 | 9 | 0.120 |
Why?
|
| Spirometry | 2 | 2025 | 25 | 0.120 |
Why?
|
| Patient Care | 1 | 2016 | 28 | 0.120 |
Why?
|
| Insulin Resistance | 1 | 2019 | 457 | 0.120 |
Why?
|
| Mutation | 2 | 2010 | 497 | 0.120 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2015 | 10 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2015 | 19 | 0.120 |
Why?
|
| Hypothyroidism | 1 | 2015 | 10 | 0.120 |
Why?
|
| Prescription Drugs | 1 | 2016 | 19 | 0.110 |
Why?
|
| Length of Stay | 1 | 2017 | 321 | 0.110 |
Why?
|
| Galectin 3 | 2 | 2014 | 4 | 0.110 |
Why?
|
| Models, Biological | 2 | 2009 | 403 | 0.110 |
Why?
|
| Brachial Artery | 2 | 2014 | 73 | 0.110 |
Why?
|
| Body Fluids | 1 | 2015 | 7 | 0.110 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2015 | 14 | 0.110 |
Why?
|
| Spouses | 1 | 2015 | 13 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 167 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 2 | 2007 | 62 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 82 | 0.110 |
Why?
|
| Relaxin | 1 | 2015 | 4 | 0.110 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2015 | 9 | 0.110 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2015 | 2 | 0.110 |
Why?
|
| Angiotensin I | 1 | 2017 | 237 | 0.110 |
Why?
|
| Adaptation, Physiological | 1 | 2015 | 54 | 0.110 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 9 | 0.110 |
Why?
|
| Probability | 3 | 2010 | 154 | 0.110 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 3 | 2020 | 16 | 0.110 |
Why?
|
| Aorta, Thoracic | 2 | 2012 | 81 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 167 | 0.100 |
Why?
|
| Albuminuria | 1 | 2015 | 172 | 0.100 |
Why?
|
| Risk Reduction Behavior | 2 | 2012 | 117 | 0.100 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 263 | 0.100 |
Why?
|
| Smoking | 2 | 2016 | 505 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 39 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2010 | 478 | 0.100 |
Why?
|
| Syndrome | 1 | 2014 | 66 | 0.100 |
Why?
|
| Gene Frequency | 3 | 2010 | 212 | 0.100 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2015 | 31 | 0.100 |
Why?
|
| Vasodilator Agents | 3 | 2022 | 62 | 0.100 |
Why?
|
| Logistic Models | 3 | 2016 | 743 | 0.100 |
Why?
|
| Microcirculation | 1 | 2014 | 66 | 0.100 |
Why?
|
| Prediabetic State | 1 | 2015 | 76 | 0.100 |
Why?
|
| Child | 1 | 2020 | 2446 | 0.100 |
Why?
|
| Fatty Acids | 2 | 2024 | 100 | 0.100 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2023 | 71 | 0.100 |
Why?
|
| Sodium | 2 | 2023 | 41 | 0.100 |
Why?
|
| Body Surface Area | 3 | 2009 | 15 | 0.100 |
Why?
|
| Anemia | 1 | 2013 | 50 | 0.100 |
Why?
|
| Energy Metabolism | 2 | 2025 | 150 | 0.100 |
Why?
|
| Angiography | 1 | 2013 | 76 | 0.090 |
Why?
|
| Isoleucine | 2 | 2010 | 6 | 0.090 |
Why?
|
| Valine | 2 | 2010 | 14 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 246 | 0.090 |
Why?
|
| Bacterial Translocation | 1 | 2012 | 8 | 0.090 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 8 | 0.090 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2003 | 26 | 0.090 |
Why?
|
| Ambulatory Care | 3 | 2009 | 111 | 0.090 |
Why?
|
| Inflammation Mediators | 2 | 2012 | 96 | 0.090 |
Why?
|
| Dilatation, Pathologic | 1 | 2012 | 20 | 0.090 |
Why?
|
| Stress, Psychological | 2 | 2006 | 229 | 0.090 |
Why?
|
| Neoplasms | 1 | 2019 | 763 | 0.090 |
Why?
|
| Polymorphism, Genetic | 2 | 2003 | 179 | 0.090 |
Why?
|
| United States Food and Drug Administration | 2 | 2026 | 52 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 112 | 0.090 |
Why?
|
| Chromosome Mapping | 3 | 2007 | 188 | 0.090 |
Why?
|
| Organ Size | 2 | 2009 | 221 | 0.090 |
Why?
|
| Housing, Animal | 1 | 2011 | 23 | 0.090 |
Why?
|
| Procollagen | 1 | 2011 | 7 | 0.090 |
Why?
|
| Patient Readmission | 2 | 2023 | 135 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2012 | 148 | 0.090 |
Why?
|
| Respiratory Function Tests | 4 | 2012 | 93 | 0.090 |
Why?
|
| Collagen Type I | 1 | 2011 | 44 | 0.090 |
Why?
|
| Comprehension | 1 | 2011 | 18 | 0.080 |
Why?
|
| Benzoyl Peroxide | 1 | 2021 | 20 | 0.080 |
Why?
|
| Cytokines | 1 | 2012 | 236 | 0.080 |
Why?
|
| Radiography | 2 | 2010 | 358 | 0.080 |
Why?
|
| Clinical Protocols | 2 | 2016 | 77 | 0.080 |
Why?
|
| Evidence-Based Medicine | 4 | 2016 | 212 | 0.080 |
Why?
|
| Macaca fascicularis | 3 | 2018 | 542 | 0.080 |
Why?
|
| Angina, Unstable | 2 | 2009 | 13 | 0.080 |
Why?
|
| Peptides | 1 | 2011 | 128 | 0.080 |
Why?
|
| Radiopharmaceuticals | 1 | 2011 | 93 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2011 | 187 | 0.080 |
Why?
|
| Rats | 5 | 2017 | 1892 | 0.080 |
Why?
|
| Tilt-Table Test | 1 | 2010 | 13 | 0.080 |
Why?
|
| Collagen | 1 | 2011 | 229 | 0.080 |
Why?
|
| Lod Score | 3 | 2009 | 68 | 0.080 |
Why?
|
| Bicycling | 1 | 2009 | 12 | 0.080 |
Why?
|
| Cardiac Volume | 1 | 2009 | 13 | 0.080 |
Why?
|
| Genotype | 5 | 2015 | 706 | 0.080 |
Why?
|
| Heart Valve Diseases | 2 | 2007 | 28 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 276 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 1073 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2009 | 15 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2009 | 164 | 0.070 |
Why?
|
| Hyperglycemia | 1 | 2009 | 85 | 0.070 |
Why?
|
| Contrast Media | 3 | 2008 | 136 | 0.070 |
Why?
|
| Sex Distribution | 2 | 2007 | 174 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2018 | 3612 | 0.070 |
Why?
|
| Lower Extremity | 1 | 2009 | 99 | 0.070 |
Why?
|
| Image Enhancement | 1 | 2008 | 66 | 0.070 |
Why?
|
| Physical Conditioning, Animal | 1 | 2008 | 35 | 0.070 |
Why?
|
| Placebos | 2 | 2021 | 69 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 767 | 0.070 |
Why?
|
| Drug Resistance | 2 | 2018 | 42 | 0.070 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2008 | 26 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2009 | 267 | 0.070 |
Why?
|
| Adipose Tissue | 3 | 2005 | 318 | 0.070 |
Why?
|
| Statistics as Topic | 3 | 2020 | 99 | 0.060 |
Why?
|
| ROC Curve | 3 | 2015 | 169 | 0.060 |
Why?
|
| Observer Variation | 4 | 2012 | 96 | 0.060 |
Why?
|
| Mitral Valve | 2 | 2007 | 33 | 0.060 |
Why?
|
| Digoxin | 1 | 2006 | 4 | 0.060 |
Why?
|
| Estrogens | 1 | 2008 | 194 | 0.060 |
Why?
|
| Hydrochlorothiazide | 1 | 2006 | 3 | 0.060 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2004 | 10 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2005 | 15 | 0.060 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2006 | 9 | 0.060 |
Why?
|
| Losartan | 1 | 2006 | 64 | 0.060 |
Why?
|
| Calcinosis | 1 | 2007 | 142 | 0.060 |
Why?
|
| Risk | 2 | 2018 | 305 | 0.060 |
Why?
|
| Heart Function Tests | 1 | 2005 | 8 | 0.060 |
Why?
|
| Ventricular Function, Right | 2 | 2016 | 17 | 0.060 |
Why?
|
| Thiazoles | 1 | 2005 | 36 | 0.050 |
Why?
|
| Data Collection | 3 | 2009 | 171 | 0.050 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2024 | 1 | 0.050 |
Why?
|
| Counseling | 2 | 2016 | 94 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2025 | 34 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2006 | 122 | 0.050 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2024 | 11 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2009 | 490 | 0.050 |
Why?
|
| Troponin I | 1 | 2024 | 20 | 0.050 |
Why?
|
| Actigraphy | 1 | 2024 | 15 | 0.050 |
Why?
|
| Italy | 2 | 2017 | 13 | 0.050 |
Why?
|
| Verapamil | 1 | 2004 | 8 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2025 | 906 | 0.050 |
Why?
|
| Benzimidazoles | 1 | 2004 | 31 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2004 | 53 | 0.050 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2003 | 25 | 0.050 |
Why?
|
| Ultrasonography, Doppler | 1 | 2003 | 23 | 0.050 |
Why?
|
| Adolescent | 3 | 2018 | 3521 | 0.050 |
Why?
|
| Permeability | 1 | 2023 | 11 | 0.050 |
Why?
|
| Vulnerable Populations | 1 | 2003 | 37 | 0.050 |
Why?
|
| Consensus | 2 | 2017 | 86 | 0.050 |
Why?
|
| Mice, Obese | 1 | 2023 | 22 | 0.050 |
Why?
|
| Diet, Reducing | 2 | 2016 | 85 | 0.050 |
Why?
|
| Ethanolamines | 1 | 2023 | 10 | 0.050 |
Why?
|
| Hydrocarbons, Brominated | 1 | 2003 | 2 | 0.050 |
Why?
|
| Endocardium | 1 | 2003 | 5 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2023 | 55 | 0.050 |
Why?
|
| Weight Gain | 2 | 2015 | 103 | 0.050 |
Why?
|
| Twins, Monozygotic | 1 | 2003 | 13 | 0.050 |
Why?
|
| Fluorocarbons | 1 | 2003 | 21 | 0.050 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2003 | 27 | 0.050 |
Why?
|
| Ergometry | 1 | 2002 | 4 | 0.050 |
Why?
|
| Natriuretic Agents | 1 | 2002 | 3 | 0.050 |
Why?
|
| Medicare | 3 | 2012 | 218 | 0.050 |
Why?
|
| Heart Defects, Congenital | 1 | 2003 | 34 | 0.050 |
Why?
|
| Mitochondrial Myopathies | 2 | 2012 | 2 | 0.050 |
Why?
|
| Catecholamines | 1 | 2002 | 17 | 0.050 |
Why?
|
| Program Evaluation | 1 | 2003 | 171 | 0.050 |
Why?
|
| Dexfenfluramine | 1 | 2002 | 1 | 0.050 |
Why?
|
| Fenfluramine | 1 | 2002 | 5 | 0.050 |
Why?
|
| Appetite Depressants | 1 | 2002 | 7 | 0.050 |
Why?
|
| Phentermine | 1 | 2002 | 9 | 0.050 |
Why?
|
| Patients | 2 | 2012 | 46 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2013 | 141 | 0.050 |
Why?
|
| Arousal | 1 | 2002 | 21 | 0.040 |
Why?
|
| Troponin | 1 | 2022 | 101 | 0.040 |
Why?
|
| Angiotensinogen | 1 | 2002 | 59 | 0.040 |
Why?
|
| Software | 2 | 2012 | 125 | 0.040 |
Why?
|
| Heart Valve Prosthesis | 1 | 2002 | 58 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 230 | 0.040 |
Why?
|
| Bioprosthesis | 1 | 2002 | 60 | 0.040 |
Why?
|
| Fibrosis | 2 | 2014 | 126 | 0.040 |
Why?
|
| Mitochondria | 1 | 2023 | 207 | 0.040 |
Why?
|
| Ventricular Pressure | 1 | 2021 | 5 | 0.040 |
Why?
|
| Heterozygote | 2 | 2015 | 60 | 0.040 |
Why?
|
| alpha Karyopherins | 1 | 2020 | 2 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2020 | 21 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 26 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 15 | 0.040 |
Why?
|
| Insulin | 1 | 2002 | 359 | 0.040 |
Why?
|
| Prosthesis Design | 2 | 2016 | 107 | 0.040 |
Why?
|
| Diet | 2 | 2014 | 382 | 0.040 |
Why?
|
| Goblet Cells | 1 | 2020 | 4 | 0.040 |
Why?
|
| Mucins | 1 | 2020 | 16 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 81 | 0.040 |
Why?
|
| Evidence-Based Practice | 1 | 2020 | 22 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2020 | 83 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2020 | 89 | 0.040 |
Why?
|
| Teichoic Acids | 1 | 2019 | 7 | 0.040 |
Why?
|
| Cell Wall | 1 | 2019 | 6 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 149 | 0.040 |
Why?
|
| Caenorhabditis elegans | 1 | 2019 | 19 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2020 | 195 | 0.040 |
Why?
|
| Hot Temperature | 1 | 2019 | 81 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2019 | 25 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 113 | 0.040 |
Why?
|
| North Carolina | 2 | 2014 | 1299 | 0.040 |
Why?
|
| Arecaceae | 1 | 2019 | 1 | 0.040 |
Why?
|
| Quercus | 1 | 2019 | 1 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2020 | 180 | 0.040 |
Why?
|
| Seeds | 1 | 2019 | 11 | 0.040 |
Why?
|
| Hypothalamus | 1 | 2019 | 22 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2019 | 75 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 2018 | 7 | 0.040 |
Why?
|
| Enterococcus | 1 | 2018 | 13 | 0.040 |
Why?
|
| Lactobacillus | 1 | 2018 | 12 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 201 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 95 | 0.030 |
Why?
|
| Health Behavior | 1 | 2019 | 213 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 57 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2017 | 11 | 0.030 |
Why?
|
| Cystatin C | 1 | 2017 | 33 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2017 | 80 | 0.030 |
Why?
|
| Rats, Inbred BN | 2 | 2008 | 31 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2017 | 85 | 0.030 |
Why?
|
| Hot Flashes | 1 | 2017 | 49 | 0.030 |
Why?
|
| Stroke | 3 | 2012 | 691 | 0.030 |
Why?
|
| Torsion, Mechanical | 1 | 2017 | 6 | 0.030 |
Why?
|
| Lysine | 1 | 2017 | 23 | 0.030 |
Why?
|
| Primates | 1 | 2017 | 128 | 0.030 |
Why?
|
| Rats, Inbred F344 | 2 | 2008 | 150 | 0.030 |
Why?
|
| Pulmonary Heart Disease | 1 | 2016 | 1 | 0.030 |
Why?
|
| Health Services Research | 1 | 2017 | 81 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2017 | 159 | 0.030 |
Why?
|
| Genetic Markers | 2 | 2009 | 124 | 0.030 |
Why?
|
| Femoral Artery | 2 | 2009 | 45 | 0.030 |
Why?
|
| Pravastatin | 1 | 2016 | 16 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 776 | 0.030 |
Why?
|
| Simvastatin | 1 | 2016 | 26 | 0.030 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 21 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 82 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2016 | 34 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2016 | 91 | 0.030 |
Why?
|
| Independent Living | 1 | 2016 | 90 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2017 | 327 | 0.030 |
Why?
|
| Research Subjects | 1 | 2016 | 19 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2016 | 16 | 0.030 |
Why?
|
| Kinetics | 1 | 2016 | 248 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2007 | 37 | 0.030 |
Why?
|
| Behavior Therapy | 1 | 2016 | 103 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2017 | 144 | 0.030 |
Why?
|
| Siblings | 2 | 2007 | 23 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2016 | 51 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2016 | 78 | 0.030 |
Why?
|
| Role | 1 | 2015 | 5 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 28 | 0.030 |
Why?
|
| Causality | 1 | 2015 | 37 | 0.030 |
Why?
|
| Publication Bias | 1 | 2015 | 7 | 0.030 |
Why?
|
| Edema, Cardiac | 1 | 2014 | 12 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 121 | 0.030 |
Why?
|
| Ethnic Groups | 1 | 2016 | 450 | 0.030 |
Why?
|
| Body Weights and Measures | 1 | 2014 | 23 | 0.030 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2014 | 19 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2013 | 6 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2013 | 45 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2013 | 69 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 896 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 317 | 0.020 |
Why?
|
| Postmenopause | 1 | 2015 | 424 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 716 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2004 | 502 | 0.020 |
Why?
|
| Propensity Score | 1 | 2012 | 47 | 0.020 |
Why?
|
| Bradycardia | 1 | 2012 | 17 | 0.020 |
Why?
|
| Lung Volume Measurements | 1 | 2012 | 4 | 0.020 |
Why?
|
| Cercopithecidae | 1 | 2011 | 11 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2011 | 12 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 97 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2012 | 181 | 0.020 |
Why?
|
| Intention | 1 | 2011 | 30 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2009 | 84 | 0.020 |
Why?
|
| Iliac Artery | 1 | 2009 | 50 | 0.020 |
Why?
|
| Bundle-Branch Block | 1 | 2009 | 22 | 0.020 |
Why?
|
| Waiting Lists | 1 | 2009 | 35 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2009 | 39 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2009 | 33 | 0.020 |
Why?
|
| Partial Pressure | 1 | 2008 | 6 | 0.020 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2008 | 10 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 2009 | 175 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 84 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 222 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 213 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2008 | 123 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2007 | 72 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2007 | 7 | 0.020 |
Why?
|
| Osteonectin | 1 | 2007 | 5 | 0.020 |
Why?
|
| Renin | 1 | 2008 | 107 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2007 | 48 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 543 | 0.020 |
Why?
|
| Health Resources | 1 | 2007 | 32 | 0.020 |
Why?
|
| Sinoatrial Node | 1 | 2006 | 4 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2007 | 106 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2007 | 87 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2007 | 90 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 128 | 0.010 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2005 | 16 | 0.010 |
Why?
|
| Genome | 1 | 2005 | 38 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2005 | 57 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 2004 | 20 | 0.010 |
Why?
|
| Quality Control | 1 | 2004 | 42 | 0.010 |
Why?
|
| Risk Management | 1 | 2004 | 22 | 0.010 |
Why?
|
| Skinfold Thickness | 1 | 2003 | 7 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2002 | 32 | 0.010 |
Why?
|
| Swine | 1 | 2002 | 229 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2002 | 72 | 0.010 |
Why?
|